Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
148 Leser
Artikel bewerten:
(0)

ZetrOZ Systems' sam Wearable Ultrasound Device Helps Osteoarthritis Patient Get Back to Living

Treating bilateral knee osteoarthritis with sustained acoustic medicine reduces pain, restores function for 76-year-old man.

TRUMBULL, CT / ACCESS Newswire / September 23, 2025 / Bilateral knee osteoarthritis was keeping Drew Sumrell from doing the things he wanted to do. Conventional treatments were not solving the problem. He found relief and a solution by including the sam® wearable ultrasound unit from ZetrOZ Systems as part of his treatment routine.

The sam® device has proven to be an effective treatment for knee osteoarthritis and many soft-tissue injuries, as documented in multiple clinical studies, providing continuous, long-duration ultrasound directly to the site of pain or injury. The treatment accelerates healing and reduces pain associated with arthritis, muscle strains, and joint injuries.

Sumrell's condition had been keeping him from one of his favorite activities, hiking, as well as limiting his ability to do household tasks, until earlier this year when the 76-year-old Boone, N.C. man started using the sam® ultrasound device as part of his treatment routine.

"I have been using my sam® ultrasound device since the end of March to treat both of my knees," Sumrell said. "After consistently using it six times a week -- three days per knee -- I began to notice a clear difference in my pain levels. I am now able to complete my daily activities with significantly less pain. I am truly thankful for the relief that sam® has given me."

Sumrell's experience shows how sam® can improve the quality of life for patients with osteoarthritis, as a safe, non-invasive, and effective method for managing chronic joint pain. The device works by producing continuous ultrasound waves in soft tissue, which decreases inflammation while increasing blood vessel diameters to improve blood flow. That augments oxygenated hemoglobin at the site and removes cytokine enzymes and cellular waste.

A study by the National Library of Medicine found that the "Sustained acoustic medicine (sam®), a multi-hour treatment, has demonstrated improved clinical outcomes for patients with knee OA." The analysis compared the costs and effectiveness of a multi-hour sam® treatment against a standard of care (SOC) over six months for managing OA symptoms. The study concluded that "the sam® wearable home-use continuous long-duration ultrasound appears to be a cost-effective therapy and should be considered when treating patients with knee OA."

The study is among the 20 Level 1-5 clinical studies and over 40 peer-reviewed articles in science, engineering and medical journals that demonstrate sam®'s effectiveness in healing soft tissue injuries. sam® is the only long-duration ultrasound device cleared by the U.S. Food & Drug Administration for home use.

For more information on the effectiveness of the sam® device, as validated by more than 3.7 million treatments of patients nationwide, please visit https://zetroz.com/ or samrecover.com.

About ZetrOZ Systems
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 48 patents and is the exclusive manufacturer and developer of the sam® product line, designed to treat acute and chronic musculoskeletal conditions.

Contact Information

Catherine Hoblin
Media Contact
choblin@zetroz.com

.

SOURCE: ZetrOZ Systems

Related Images



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/zetroz-systems-sam-wearable-ultrasound-device-helps-osteoarthritis-pa-1074690

© 2025 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.